Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Net Income (2016 - 2025)

Historic Net Income for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$742000.0.

  • Guided Therapeutics' Net Income fell 1345.57% to -$742000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 2236.17%. This contributed to the annual value of -$2.4 million for FY2024, which is 3072.51% up from last year.
  • Latest data reveals that Guided Therapeutics reported Net Income of -$742000.0 as of Q3 2025, which was down 1345.57% from -$811000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Net Income high stood at $68000.0 for Q3 2021, and its period low was -$1.8 million during Q4 2022.
  • In the last 5 years, Guided Therapeutics' Net Income had a median value of -$677000.0 in 2023 and averaged -$745000.0.
  • Its Net Income has fluctuated over the past 5 years, first surged by 8467.92% in 2021, then crashed by 172058.82% in 2022.
  • Guided Therapeutics' Net Income (Quarter) stood at -$444000.0 in 2021, then plummeted by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then crashed by 68.91% to -$652000.0 in 2024, then dropped by 13.8% to -$742000.0 in 2025.
  • Its last three reported values are -$742000.0 in Q3 2025, -$811000.0 for Q2 2025, and -$427000.0 during Q1 2025.